In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Entellus Medical raises $30mm via Series D financing

Executive Summary

Entellus Medical (developing less invasive ENT devices) has raised $30mm in Series D money. New investor Essex Woodlands Health Ventures led (and contributes a board member) and was joined by current shareholders Split Rock Partners and SV Life Sciences. Entellus will use the funds to add members to its sales and customer support departments and to promote the FinESS chronic sinusitis treatment for use in the physician's office. The company is planning a 2010 US launch and preparing for international marketing.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies